Evidence map›Paper›PMID 34251893›Full record

ArticleCirculation2021

Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.

G Michael Felker, Javed Butler, Nasiren E Ibrahim, Ileana L Piña, Alan Maisel, Devavrat Bapat, Alexander Camacho, Jonathan H Ward, Kristin M Williamson, Scott D Solomon and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Mitral Regurgitation in Female Patients: Sex Differences and Disparities.Journal of the Society for Cardiovascular Angiography & Interventions
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

G Michael FelkerDuke Clinical Research Institute and Duke University School of Medicine, Durham, NC (G.M.F.).
Javed ButlerUniversity of Mississippi Medical Center, Jackson (J.B.).
Nasiren E IbrahimMassachusetts General Hospital, Boston (N.E.I., J.L.J., D.B., A.C.).
Ileana L PiñaWayne State University, Detroit, MI (I.L.P.).
Alan MaiselUniversity of California-San Diego (A.M.).
Devavrat BapatMassachusetts General Hospital, Boston (N.E.I., J.L.J., D.B., A.C.).
Alexander CamachoMassachusetts General Hospital, Boston (N.E.I., J.L.J., D.B., A.C.).
Jonathan H WardNovartis Pharmaceuticals, East Hanover, NJ (J.H.W., K.M.W.).
Kristin M WilliamsonNovartis Pharmaceuticals, East Hanover, NJ (J.H.W., K.M.W.).
Scott D SolomonBrigham and Women's Hospital, Boston, MA (S.D.S.).
James L JanuzziMassachusetts General Hospital, Boston (N.E.I., J.L.J., D.B., A.C.).
PROVE-HF Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsChronic DiseaseDefibrillators, ImplantableFemaleHeart FailureHumansMaleValsartanAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundssacubitrilValsartandefibrillators, implantableheart failuresacubitril-valsartanstroke volume

Identifiers

PMID34251893
PMCPMC8270225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.